Drugs / Thymic peptides
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04771013 | Feb → May 2021 | COVID-19 | Catholic University of Honduras | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymic peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04771013 ↗ |
| Modality | Peptide | “lyophilized thymic peptides” NCT04771013 ↗ |
| Route | Oral | “250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water” NCT04771013 ↗ |